



European community-based intervention project will use Monsenso's platform to prevent mental illness

15.12.2022 12:17:50 CET | Monsenso | Company Announcement

Together with a European consortium of partners, Monsenso has received a grant letter on a new community-based intervention project that includes development and trial of a digital health intervention delivered on Monsenso's platform to prevent mental illness among vulnerable groups.

Company announcement no. 16-2022

Monsenso (publ.) (Nasdaq First North Growth Market Denmark: Ticker MONSO) is obligated to publish the information in compliance with the EU Market Abuse Regulation.

Copenhagen, 2022.12.15

Global trends such as war, economic crisis, climate changes, migration, pandemics and ageing population place increasing stress and pressure on European societies. To be able to adapt to fast-changing situations, scalable intervention programmes targeted at building resilience and enhancing self-help competency to prevent mental illness are needed.

Upon receiving this grant letter, Monsenso is now entering into grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, AI and community mental health providers across Europe. The aim of the project is to develop and trial an AI-enabled personalised self-care program based on Monsenso's platform to help prevent mental illness for high-risk groups. The five-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 5.7 mio to Monsenso.

- This is the second AI-enabled personalised therapy project that we plan to start in the coming year, and it comes after finalising another European research project this year, where results showed significant effect of delivering digital cognitive behavioral therapy for prevention of mental illness. We will build on the evidence and experience of previous projects and further develop our platform to provide personalised, AI-driven digital programs for people at risk of developing mental illness, so that they can get easy and timely access to evidence-based support, says Thomas Lethenborg, CEO of Monsenso.

Further information on the project including consortium members, funding program and population groups targeted will be communicated upon signature of a grant agreement, which is expected in Q1 of 2023.

Financial expectations

The project does not impact Monsenso's financial expectations for 2022, but it is expected to contribute to the growth in 2023 and beyond.

Further information:

Monsenso:

CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsensso.com

Chairman of the board
Peter Mørch Eriksen
Tel. +45 51 99 66 00
E-mail: petermorcheriksen@outlook.com

Certified Adviser:

Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit

www.monsenso.com

Attachments

- [Download announcement as PDF.pdf](#)
- [Patient with smartphone.jpg](#)
- [Clinician with clinical web portal.jpg](#)